ASX - By Stock
|
IMM |
Re:
Ann: Appendix 4E & 2022 Full Year Statutory Accounts
|
|
megamutts
|
12 |
4.4K |
13 |
31/08/22 |
31/08/22 |
ASX - By Stock
|
12
|
4.4K
|
13
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Prescient Therapeutics Launches Share Purchase Plan
|
|
megamutts
|
181 |
65K |
9 |
24/08/22 |
24/08/22 |
ASX - By Stock
|
181
|
65K
|
9
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
9 |
17/08/22 |
17/08/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
9
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
8 |
17/08/22 |
17/08/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
3 |
17/08/22 |
17/08/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
3
|
|
ASX - By Stock
|
PTX |
Re:
PTX Media related
|
|
megamutts
|
1.5K |
649K |
16 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
1.5K
|
649K
|
16
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
18 |
10/08/22 |
10/08/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
18
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
7 |
10/08/22 |
10/08/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
14 |
10/08/22 |
10/08/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
14
|
|
ASX - By Stock
|
IMM |
Re:
Ann: TACTI-002 2nd line lung cancer data presented at 2022 WCLC
|
|
megamutts
|
51 |
22K |
4 |
10/08/22 |
10/08/22 |
ASX - By Stock
|
51
|
22K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
updated chart
|
|
megamutts
|
3.2K |
1.2M |
13 |
01/08/22 |
01/08/22 |
ASX - By Stock
|
3.2K
|
1.2M
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Acadia submits Rett Syndrome New Drug Application to the FDA
|
|
megamutts
|
95 |
48K |
3 |
30/07/22 |
30/07/22 |
ASX - By Stock
|
95
|
48K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
megamutts
|
382 |
194K |
2 |
25/07/22 |
25/07/22 |
ASX - By Stock
|
382
|
194K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
megamutts
|
382 |
194K |
0 |
24/07/22 |
24/07/22 |
ASX - By Stock
|
382
|
194K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Positive ORR in 1st line NSCLC from ph 2 TACTI-002 trial
|
|
megamutts
|
70 |
29K |
6 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
70
|
29K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Positive ORR in 1st line NSCLC from ph 2 TACTI-002 trial
|
|
megamutts
|
70 |
29K |
2 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
70
|
29K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
megamutts
|
382 |
194K |
11 |
07/04/22 |
07/04/22 |
ASX - By Stock
|
382
|
194K
|
11
|
|
ASX - By Stock
|
PTX |
Re:
PTX Media related
|
|
megamutts
|
1.5K |
649K |
27 |
05/04/22 |
05/04/22 |
ASX - By Stock
|
1.5K
|
649K
|
27
|
|
ASX - By Stock
|
PTX |
Re:
PTX Media related
|
|
megamutts
|
1.5K |
649K |
23 |
28/03/22 |
28/03/22 |
ASX - By Stock
|
1.5K
|
649K
|
23
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
4 |
28/03/22 |
28/03/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
11 |
26/03/22 |
26/03/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
11
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
8 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
2 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
6 |
09/02/22 |
09/02/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
6
|
|
ASX - By Stock
|
PTX |
Re:
updated chart
|
|
megamutts
|
3.2K |
1.2M |
7 |
29/01/22 |
29/01/22 |
ASX - By Stock
|
3.2K
|
1.2M
|
7
|
|
ASX - By Stock
|
EBR |
Re:
EBR news
|
|
megamutts
|
29 |
17K |
2 |
14/01/22 |
14/01/22 |
ASX - By Stock
|
29
|
17K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
12 |
10/01/22 |
10/01/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
12
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
megamutts
|
2.7K |
1.1M |
14 |
06/01/22 |
06/01/22 |
ASX - By Stock
|
2.7K
|
1.1M
|
14
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Change of Registered Office Address
|
|
megamutts
|
20 |
6.3K |
14 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
20
|
6.3K
|
14
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
megamutts
|
128 |
771K |
3 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
128
|
771K
|
3
|
|
ASX - By Stock
|
PTX |
Re:
updated chart
|
|
megamutts
|
3.2K |
1.2M |
12 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
3.2K
|
1.2M
|
12
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Global Webcast Slides to Discuss Clinical Results
|
|
megamutts
|
22 |
9.9K |
5 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
22
|
9.9K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
ACADIA earnings
|
|
megamutts
|
112 |
54K |
1 |
09/11/21 |
09/11/21 |
ASX - By Stock
|
112
|
54K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
IMM CHART / SP
|
|
megamutts
|
213 |
89K |
5 |
05/11/21 |
05/11/21 |
ASX - By Stock
|
213
|
89K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
Short Interest (USA)
|
|
megamutts
|
7 |
3.8K |
5 |
04/11/21 |
04/11/21 |
ASX - By Stock
|
7
|
3.8K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Receives A$3.4 Mln Research And Development Tax Incentive From French Government
|
|
megamutts
|
3 |
1.5K |
0 |
30/09/21 |
30/09/21 |
ASX - By Stock
|
3
|
1.5K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
megamutts
|
743 |
339K |
3 |
24/09/21 |
24/09/21 |
ASX - By Stock
|
743
|
339K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
megamutts
|
743 |
339K |
5 |
19/09/21 |
19/09/21 |
ASX - By Stock
|
743
|
339K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
Ptx to 10 bag by this time next year
|
|
megamutts
|
840 |
324K |
16 |
14/09/21 |
14/09/21 |
ASX - By Stock
|
840
|
324K
|
16
|
|
ASX - By Stock
|
IMM |
Re:
CHECKPOINT INHIBITORS - What The?
|
|
megamutts
|
30 |
12K |
2 |
14/09/21 |
14/09/21 |
ASX - By Stock
|
30
|
12K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trofinetide Rett syndrome clinical trial in girls aged 2-5
|
|
megamutts
|
30 |
15K |
0 |
06/09/21 |
06/09/21 |
ASX - By Stock
|
30
|
15K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trofinetide Rett syndrome clinical trial in girls aged 2-5
|
|
megamutts
|
30 |
15K |
14 |
06/09/21 |
06/09/21 |
ASX - By Stock
|
30
|
15K
|
14
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trofinetide Rett syndrome clinical trial in girls aged 2-5
|
|
megamutts
|
30 |
15K |
11 |
05/09/21 |
05/09/21 |
ASX - By Stock
|
30
|
15K
|
11
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
megamutts
|
743 |
339K |
7 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
743
|
339K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Recruitment of patients completed for Part B of TACTI-002
|
|
megamutts
|
22 |
9.1K |
5 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
22
|
9.1K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep's partner, EOC Pharma, expands efti trial pipeline
|
|
megamutts
|
9 |
8.7K |
0 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
9
|
8.7K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Appendix 4E & 2021 Full Year Statutory Accounts
|
|
megamutts
|
15 |
6.0K |
1 |
30/08/21 |
30/08/21 |
ASX - By Stock
|
15
|
6.0K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Updated MST report - target of $3.68 a share
|
|
megamutts
|
219 |
111K |
6 |
17/08/21 |
17/08/21 |
ASX - By Stock
|
219
|
111K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
ESMO 2021
|
|
megamutts
|
128 |
48K |
1 |
16/08/21 |
16/08/21 |
ASX - By Stock
|
128
|
48K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Updated MST report - target of $3.68 a share
|
|
megamutts
|
219 |
111K |
4 |
13/08/21 |
13/08/21 |
ASX - By Stock
|
219
|
111K
|
4
|
|